A phase 3 study assessing the use pregabalin as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized tonic-clonic (PGTC) seizures did not meet its primary endpoint to ...
BOSTON — Preliminary results from a meta-analysis have shown that antiepileptic drugs (AEDs) approved for adults with primary generalized tonic-clonic (PGTC) seizures are also effective in children ...
GlaxoSmithKline’s antiseizure drug, Lamictal® (lamotrigine), was approved for a new epilepsy indication—one of the most serious forms of epilepsy, primary generalized tonic-clonic (PGTC) seizures.
On September 16, SK Biopharmaceuticals announced that it has obtained positive top-line results from a Phase 3 clinical trial evaluating cenobamate (U.S. brand name XCOPRI®), its innovative ...
Phase III study demonstrates significant improvements in seizure freedom and seizure reduction in people living with this severe type of epilepsy Fycompa ® (perampanel) today received positive opinion ...
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that 24-month data on generalized tonic-clonic (GTC) seizures in people with drug-resistant epilepsy (DRE) ...
The Key Tonic clonic Seizure Companiesin theamrket include - Emory University, Pfizer, GlaxoSmithKline, Eisai Inc., Xenon Pharmaceuticals, UCB Pharma, Johnson ...
The FDA also approved Vimpat Injection for use in pediatric patients 4 years of age and older. The Food and Drug Administration (FDA) has approved Vimpat ® (lacosamide; UCB) as adjunctive therapy in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback